TB-500

Background

TB‑500 is a synthetic peptide corresponding to a truncated fragment of thymosin β4 (Tβ4), a 43–amino acid actin‑sequestering peptide widely expressed in mammalian cells and originally isolated from thymus extracts in the 1960s–1970s.[1][2] Tβ4 was identified as a major intracellular G‑actin binding protein and subsequently implicated in tissue repair, angiogenesis, and cytoprotection in multiple organs.[2] TB‑500 is marketed in the “research chemical” and sports‑enhancement sectors as a putative healing/regenerative peptide, typically described as comprising amino acids 17–23 or overlapping core motifs of Tβ4, although commercial preparations are not standardized and detailed characterization is rarely disclosed.[1]

TB‑500 itself has not been formally characterized in peer‑reviewed pharmacological studies; most mechanistic and efficacy claims are extrapolated from work on full‑length thymosin β4 or proprietary Tβ4‑based biologics (e.g., ACT‑1, RGN‑137, RGN‑259).[1][2][3] The peptide is unapproved for medical use and is banned in competitive sports by the World Anti‑Doping Agency (WADA) as an “unapproved substance.”[1]

Mechanism of action

Relationship to thymosin β4

Thymosin β4 binds monomeric G‑actin, regulating actin polymerization, cell motility, and cytoskeletal rearrangement.[2] Structure–function work identified the LKKTET motif (residues 17–22) as critical for actin binding and several downstream biological activities, including promotion of cell migration and wound repair.[2] TB‑500 products are generally described as synthetic peptides containing or centered around this motif, with the intent of reproducing a subset of Tβ4’s actions.[1]

Proposed targets and pathways (inferred from Tβ4)

Direct receptor targets for TB‑500 have not been defined. Studies with Tβ4 and related peptides suggest multiple mechanisms:

• Actin sequestration and cell migration: Tβ4 forms 1:1 complexes with G‑actin and promotes lamellipodia formation, enhancing keratinocyte, endothelial, and fibroblast migration into wound beds.[2]
• Angiogenesis: Tβ4 upregulates vascular endothelial growth factor (VEGF) and increases endothelial cell migration and tubule formation in vitro and in corneal and dermal wound models.[2][3]
• Anti‑apoptotic and cytoprotective effects: In cardiac and neural tissues, Tβ4 activates PI3K–Akt and integrin‑linked kinase pathways and reduces caspase‑3 activation, contributing to cell survival after ischemic injury.[2][3]
• Anti‑inflammatory and pro‑repair signaling: Tβ4 modulates NF‑κB signaling, decreases pro‑inflammatory cytokines, and enhances macrophage phenotype shifts toward pro‑resolution states in rodent models.[2][3]

Because TB‑500 represents only a fragment of Tβ4, it is uncertain which of these mechanisms it can reproduce, and whether pharmacokinetics or tissue distribution differ from the parent peptide. No peer‑reviewed binding, signaling, or pharmacokinetic data specific to TB‑500 were identified.[1]

Evidence summary

Preclinical evidence (thymosin β4 and fragments)

Most data relevant to TB‑500 derive from studies of full‑length Tβ4 or proprietary derivatives:

• Dermal wound healing: In a murine full‑thickness skin wound model (n≈20–30 per group), topical or systemic Tβ4 accelerated re‑epithelialization and increased collagen deposition and angiogenesis compared with controls.[2] Similar effects were reported in diabetic and ischemic wound models.[2]
• Ocular surface injury: In rabbits with alkali‑induced corneal injury (n=16), topical Tβ4 accelerated corneal re‑epithelialization and reduced inflammation.[3] These findings supported development of ophthalmic formulations such as RGN‑259.[3]
• Myocardial infarction: In mouse and rat infarction models (typical n=8–15 per group), systemic Tβ4 reduced infarct size, enhanced cardiomyocyte survival, increased capillary density, and improved left‑ventricular function.[2][3]
• Central nervous system injury: Rodent stroke and spinal cord injury models demonstrated enhanced neurogenesis, axonal sprouting, and functional recovery with Tβ4 treatment.[2]

Experimental work with isolated Tβ4 fragments containing the LKKTET motif showed retention of some actin‑binding and cell‑migration–promoting properties in vitro.[2] However, translational in vivo data for these fragments are sparse and fragment sequences do not necessarily correspond to TB‑500 as sold commercially.

Human data

No controlled clinical trials of TB‑500 were identified. Available human data pertain to Tβ4‑based investigational products:

• Chronic skin ulcers (RGN‑137): In a phase 2 trial in patients with venous stasis ulcers (n=72), topical Tβ4 (RGN‑137) showed a non‑significant trend toward greater wound area reduction versus placebo; safety was acceptable.[3]
• Epidermolysis bullosa (RGN‑137): An open‑label study in inherited epidermolysis bullosa (n=14) reported acceptable local tolerability and signals of wound healing, but lacked a control group.[3]
• Ocular indications (RGN‑259): Phase 2 and 3 trials in dry eye disease and neurotrophic keratopathy tested Tβ4‑containing eye drops (sample sizes typically 72–317 subjects). Some studies reported improvements in corneal staining and symptom scores, though results have been mixed and product development has been limited to investigational use.[3]

A 2023 critical review of BPC‑157 and TB‑500 highlighted that no peer‑reviewed clinical studies of TB‑500 itself in humans were identified, despite widespread anecdotal use in sports communities.[1] The review emphasized a large gap between preclinical Tβ4 data and any evidence for TB‑500 in human therapy.[1]

Clinical and research uses

Approved uses

TB‑500 is not approved as a medicinal product by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other major regulators.[1] No TB‑500‑specific New Drug Application (NDA), Biologics License Application (BLA), or centralized EU marketing authorization was identified.

Tβ4‑based products (e.g., RGN‑137, RGN‑259) have reached phase 2–3 development for ocular and dermatologic indications but, as of the latest available regulatory documentation, have not received full marketing approval in the US or EU.[3]

Investigational and off‑label contexts

• Sports and musculoskeletal injury: TB‑500 is promoted in non‑regulated settings for recovery from tendon, ligament, and muscle injuries, often in combination with other peptides such as BPC‑157.[1] The 2024 review categorizes TB‑500 as part of the “grey zone” of pharmacology, noting extensive anecdotal use among athletes with no supporting clinical trials.[1]
• Wound healing and organ protection: Any potential use of TB‑500 for cutaneous wounds, cardiac repair, or neuroprotection is extrapolated from Tβ4 studies and remains speculative.[2][3]

Research on Tβ4 and its fragments continues primarily in preclinical models focused on wound healing, ischemic organ injury, and fibrosis.[2][3] There is limited published work that directly uses the label “TB‑500” in experimental systems, and such studies often lack detailed structural characterization.[1]

Dosing context

Because TB‑500 is not an approved drug, there is no standardized, evidence‑based dosing regimen. Published clinical trials involving Tβ4‑based investigational products report route‑ and formulation‑specific regimens that cannot be directly translated to TB‑500:

• Topical dermatologic Tβ4 (RGN‑137): Applied to chronic skin ulcers once or twice daily for several weeks; doses expressed as mg per gram of gel.[3]
• Ophthalmic Tβ4 (RGN‑259): Eye drops administered multiple times daily over several weeks in dry eye and neurotrophic keratopathy trials.[3]
• Systemic Tβ4 in animals: Rodent myocardial infarction and stroke models commonly used intraperitoneal or intravenous doses in the range of 0.3–6 mg/kg, administered once to several times over the first days post‑injury.[2][3]

These regimens pertain to full‑length Tβ4 and were selected empirically for preclinical or early‑phase clinical research, not as therapeutic standards. Reported TB‑500 dosing practices on non‑scientific websites vary widely and are not supported by peer‑reviewed pharmacokinetic, safety, or efficacy data.[1]

Safety profile

Non‑clinical and clinical safety of thymosin β4

Tβ4 has generally shown a favorable safety profile in animal toxicology studies and early‑phase human trials:

• Repeated‑dose studies in rodents and non‑human primates reported no major organ toxicity at exposures above those used in efficacy studies.[2]
• Topical Tβ4 (RGN‑137) in chronic wound and epidermolysis bullosa patients showed mainly mild local reactions (erythema, pruritus) without significant systemic adverse events.[3]
• Ophthalmic Tβ4 (RGN‑259) trials reported predominantly mild eye irritation, transient blurred vision, and instillation‑site discomfort, with similar incidence in active and placebo groups.[3]

No consistent signals of immunogenicity, pro‑tumorigenic activity, or serious systemic toxicity have emerged in these limited studies, but sample sizes were modest and follow‑up durations relatively short.[2][3]

Safety uncertainties specific to TB‑500

The safety profile of TB‑500 in humans is largely unknown:

• There are no formal toxicology studies, dose‑escalation trials, or long‑term safety evaluations of TB‑500 in peer‑reviewed literature.[1]
• Commercial preparations vary in purity, sequence, and excipients; analytical verification is rarely provided, raising concerns about contamination, incorrect dosing, and batch‑to‑batch variability.[1]
• Theoretical risks, extrapolated from Tβ4 biology, include potential effects on angiogenesis, fibrosis, and tumor biology, as actin dynamics and pro‑angiogenic signaling can influence tumor progression. Existing Tβ4 studies have not conclusively demonstrated pro‑cancer effects, but they have not been powered for oncologic safety outcomes.[2]

Pharmacovigilance data are unavailable because TB‑500 is used outside regulated medical systems. Reported adverse effects in anecdotal sources (e.g., injection‑site pain, edema, headache, fatigue) cannot be quantified or causally attributed.

Contraindications and cautions (theoretical)

Given the absence of systematic data, no evidence‑based list of contraindications exists for TB‑500. Based on mechanism and regulatory status:

• Use in individuals with active malignancy or history of cancer could be of concern due to theoretical pro‑angiogenic and pro‑migration effects inferred from Tβ4.[2]
• Use with other experimental regenerative agents (e.g., growth factors, unapproved peptides) may result in unpredictable interactions.[1]
• Self‑administration of unregulated injectable products carries standard risks of infection, improper administration, and dosing errors.

These considerations remain speculative and highlight the need for formal safety evaluation before any therapeutic use.

Regulatory status

• United States (FDA): TB‑500 does not appear in FDA databases as an approved drug, biologic, or licensed compounded preparation. No Investigational New Drug (IND) applications specifically for TB‑500 are publicly listed. Tβ4‑based products (RGN‑137, RGN‑259) have been studied under IND as investigational agents but have not received marketing approval.[3]
• European Union (EMA and national authorities): No centralized EMA marketing authorization or national authorization in EU member states for TB‑500 was identified. Tβ4‑related products remain investigational.[3]
• Doping control: The World Anti‑Doping Agency (WADA) classifies TB‑500 and related thymosin β4 fragments as Class S0 “Non‑approved substances”, prohibiting their use in all sports.[1]
• Research chemical status: TB‑500 is commonly sold online under “for research only” disclaimers, outside medicinal product regulations, with no quality, efficacy, or safety oversight.[1]

Overall, TB‑500 remains an unapproved, experimentally uncharacterized peptide fragment, with its putative regenerative effects inferred indirectly from thymosin β4 research rather than demonstrated in controlled human studies.[1][2][3]